GENELUX Corp GNLX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-55.62
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $8,000 | -$32.1M | — | -$26.4M | $11.5M |
| 2024 | $8,000 | -$29.9M | — | -$21.6M | $26.3M |
| 2023 | $170,000 | -$28.3M | — | -$21.3M | $19.5M |
| 2022 | $11.1M | -$5.2M | — | -$3.6M | -$35.8M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Pulisic Matthew | Chief Financial Officer | 2026-06-16 | Grant | 278,906 | — |
| Groen Eric | General Counsel | 2026-06-16 | Grant | 233,957 | — |
| Cappello Joseph | Chief Technical Officer | 2026-06-16 | Grant | 174,841 | — |
| Tyree James L | director | 2026-06-16 | Grant | 28,409 | — |
| Zindrick Thomas | President and CEO | 2026-06-16 | Grant | 730,601 | — |
| Thomas John | director | 2026-06-16 | Grant | 28,409 | — |
| Mirabelli Mary | director | 2026-06-16 | Grant | 28,409 | — |
| Yu Yong | Chief Scientific Officer | 2026-06-16 | Grant | 119,318 | — |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -55.62 (distress)
- Working capital / assets 0.468
- Retained earnings / assets -14.902
- EBIT / assets -1.746
- Equity / liabilities 1.543
Source: SEC EDGAR filings · CIK 0001231457 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.